Developing as a noteworthy advance in the battle against obesity, the drug is capturing considerable interest . It combines effects of two established GLP-1 receptor agonists, semaglutide , plus an unique glucose-dependent incretin component. Preliminary patient results have indicated impressive body reduction in people with a high BMI , possibly